Unknown PHASE4 INTERVENTIONAL NCT00196417

The HIT-TRAP Trial

Randomized-Double Blind Trial to Assess the Incidence and Clinical Relevance of Heparin-Induced Thrombocytopenia (HIT) Antibodies in Trauma Patients Treated With Unfractionated or Low-Molecular Weight Heparin, the HIT-TRAP Trial

Sponsor: Novartis

Conditions Heparin-Induced Thrombocytopenia

Interventions Standard heparin (UFH) versus certoparin (LMWH)

Updated 4 times since 2017 Last updated: Sep 12, 2005 Started: Jan 31, 2003 Completion: Nov 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Heparin-Induced Thrombocytopenia, this trial is ongoing. The trial is conducted by Novartis and has accumulated 4 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jan 2017 — Jan 2021 [monthly]

Unknown Status PHASE4

First recorded

Jan 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis
University Medicine Greifswald

Data source: University Medicine Greifswald

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Greifswald, Germany